195 related articles for article (PubMed ID: 22672626)
1. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB).
Goldman HB
BJU Int; 2013 Jan; 111(1):8. PubMed ID: 22672626
[No Abstract] [Full Text] [Related]
2. Re: Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB).
Wein AJ
J Urol; 2013 Nov; 190(5):1815. PubMed ID: 24120791
[No Abstract] [Full Text] [Related]
3. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB).
Mohee A; Khan A; Harris N; Eardley I
BJU Int; 2013 Jan; 111(1):106-13. PubMed ID: 22672569
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial.
Abdel-Meguid TA
J Urol; 2010 Dec; 184(6):2423-8. PubMed ID: 20952003
[TBL] [Abstract][Full Text] [Related]
5. Intravesical electromotive botulinum toxin type A administration--part II: Clinical application.
Kajbafzadeh AM; Ahmadi H; Montaser-Kouhsari L; Sharifi-Rad L; Nejat F; Bazargan-Hejazi S
Urology; 2011 Feb; 77(2):439-45. PubMed ID: 20800886
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
Herschorn S; Gajewski J; Ethans K; Corcos J; Carlson K; Bailly G; Bard R; Valiquette L; Baverstock R; Carr L; Radomski S
J Urol; 2011 Jun; 185(6):2229-35. PubMed ID: 21497851
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin injections for adults with overactive bladder syndrome.
Duthie JB; Vincent M; Herbison GP; Wilson DI; Wilson D
Cochrane Database Syst Rev; 2011 Dec; (12):CD005493. PubMed ID: 22161392
[TBL] [Abstract][Full Text] [Related]
8. Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity.
Dowson C; Khan MS; Dasgupta P; Sahai A
Nat Rev Urol; 2010 Dec; 7(12):661-7. PubMed ID: 21139642
[TBL] [Abstract][Full Text] [Related]
9. Long-term compliance and results of intravesical botulinum toxin A injections in male patients.
Rahnama'i MS; Marcelissen TAT; Brierley B; Schurch B; de Vries P
Neurourol Urodyn; 2017 Sep; 36(7):1855-1859. PubMed ID: 28084637
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of intravesical injections of botulinum toxin type A in patients with refractory idiopathic overactive bladder.
Juszczak K; Adamczyk P; Maciukiewicz P; Drewa T
Pharmacol Rep; 2018 Dec; 70(6):1133-1138. PubMed ID: 30317128
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin--a new therapeutic agent in girls with non-neurogenic overactive bladder--a case report and review of the literature.
Kulik-Rechberger B; Piechuta L; Miotła P; Skorupski P; Rechberger T
Ginekol Pol; 2010 Nov; 81(11):870-3. PubMed ID: 21361152
[TBL] [Abstract][Full Text] [Related]
12. Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis.
Chen JL; Kuo HC
Investig Clin Urol; 2020 Feb; 61(Suppl 1):S33-S42. PubMed ID: 32055752
[TBL] [Abstract][Full Text] [Related]
13. Intradetrusor botulinum toxin injections for neurogenic overactive bladder: are we there yet?
Lemack GE
Eur Urol; 2008 Feb; 53(2):240-1. PubMed ID: 17997019
[No Abstract] [Full Text] [Related]
14. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.
Veeratterapillay R; Harding C; Teo L; Vasdev N; Abroaf A; Dorkin TJ; Pickard RS; Hasan T; Thorpe AC
Int J Urol; 2014 Feb; 21(2):175-8. PubMed ID: 23819724
[TBL] [Abstract][Full Text] [Related]
15. Editorial comment on: histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.
Haferkamp A
Eur Urol; 2008 Jun; 53(6):1253. PubMed ID: 18343561
[No Abstract] [Full Text] [Related]
16. Applicability of botulinum toxin type A in paediatric neurogenic bladder management.
Scheepe JR; Blok BF; 't Hoen LA
Curr Opin Urol; 2017 Jan; 27(1):14-19. PubMed ID: 27748667
[TBL] [Abstract][Full Text] [Related]
17. Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder.
Ellsworth P; Travis M
Urol Nurs; 2014; 34(4):165-71. PubMed ID: 25233617
[TBL] [Abstract][Full Text] [Related]
18. Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder.
Kantartzis K; Shepherd J
Curr Opin Obstet Gynecol; 2012 Oct; 24(5):331-6. PubMed ID: 22922403
[TBL] [Abstract][Full Text] [Related]
19. Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure.
Karsenty G; Baverstock R; Carlson K; Diaz DC; Cruz F; Dmochowski R; Fulford S; Giannantoni A; Heesakkers J; Kaufmann A; Peyrat L; Thavaseelan J; Dasgupta P
Int J Clin Pract; 2014 Jun; 68(6):731-42. PubMed ID: 24472109
[TBL] [Abstract][Full Text] [Related]
20. [Injection of botulinum toxin (BTX-A) in children with bladder dysfunction due to detrusor overactivity].
Romero RM; Rivas S; Parente A; Fanjul M; Angulo JM
Actas Urol Esp; 2011 Feb; 35(2):89-92. PubMed ID: 21256633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
